Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
BMJ Case Rep ; 17(5)2024 May 06.
Article in English | MEDLINE | ID: mdl-38719261

ABSTRACT

Olmesartan is an angiotensin II receptor blocker licensed for the treatment of hypertension. It can cause a sprue-like enteropathy (SLE), characterised by chronic diarrhoea, weight loss and villous atrophy. Transiently raised anti-tissue transglutaminase (ATTG) antibody has also been rarely reported in the literature.We describe the case of a woman in her mid-50s, who presented with a history of intermittent loose stools over 1 year, associated with significant weight loss. She had two marginally raised serum ATTG antibody tests during her work-up.After extensive investigations, she was diagnosed with olmesartan-induced enteropathy. On subsequent follow-up, her symptoms had resolved with cessation of her olmesartan therapy.This case adds to existing literature, highlighting the importance of considering olmesartan as a possible differential diagnosis for SLE. It also reports the presence of a raised ATTG antibody which is infrequently reported in this context.


Subject(s)
Diarrhea , Imidazoles , Tetrazoles , Transglutaminases , Weight Loss , Humans , Female , Imidazoles/adverse effects , Diarrhea/chemically induced , Tetrazoles/adverse effects , Middle Aged , Transglutaminases/immunology , Diagnosis, Differential , Angiotensin II Type 1 Receptor Blockers/adverse effects , Autoantibodies/blood , Protein Glutamine gamma Glutamyltransferase 2 , Chronic Disease , Celiac Disease/diagnosis , GTP-Binding Proteins/immunology , GTP-Binding Proteins/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...